Sanofi is offering to buy Dutch biotechnology company Kiadis for 308 million euros ($358.4 million) to boost its range of immunotherapy products.
The French drugmaker will offer 5.45 euros in cash, the companies said in a joint statement on Monday, a premium of 272% to Kiadis' closing share price on Oct. 30.
Shares in Kiadis, focused on cell-based immunotherapy products for the treatment of cancer, were up 245% in early trading. Sanofi shares were up 1.18%.
Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells.
"We
The French drugmaker will offer 5.45 euros in cash, the companies said in a joint statement on Monday, a premium of 272% to Kiadis' closing share price on Oct. 30.
Shares in Kiadis, focused on cell-based immunotherapy products for the treatment of cancer, were up 245% in early trading. Sanofi shares were up 1.18%.
Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells.
"We